This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Synta's Lung Cancer Drug Struggles to Remain Relevant

Stocks in this article: SNTABMYMRK

CHICAGO ( TheStreet) -- The efficacy of Synta Pharmaceuticals' (SNTA) lung cancer drug ganetespib is weakening over time, which should raise even more concerns about the ongoing phase III clinical trial.

Snyta shares are down 17% to $6.15 in early Monday trading.

The latest update from the phase II "Galaxy-1" study, which compares ganetespib plus docetaxel against docetaxel alone in second-line non-small cell lung cancer, are being presented Monday during the American Society of Clinical Oncology (ASCO) annual meeting:

The overall survival hazard ratio for the 252 adenocarcinoma patients is 0.82, which translates into an 18 percent reduction in the risk of death. Median overall survival for ganetespib/docetaxel was 9.8 months compared to 7.4 months for docetaxel.

The result was not statistically significant and worse than the previous update of the Galaxy-1 study presented last September when the hazard ratio was 0.69, or a 31 percent reduction in the risk of death.

Synta didn't wait for final data from Galaxy-1 before starting to enroll patients in a phase III study of ganetespib in second-line lung cancer. This larger, Galaxy-2 study excludes patients who are deemed to be "rapid progressors" -- defined as patients who responded poorly to first-line therapy. In order to qualify to entry into Galaxy-2, patients have to be stable (no tumor growth) following first-line therapy for at least six months. Call these patients "normal progressors" for lack of a better term.

On Monday, Synta released an update on the subset of 176 "normal progressors" from the Galaxy-1 study. Again, the survival trend narrowed.

The latest overall survival hazard ratio is 0.61, or a 39 percent reduction in the risk of death. At the median, ganetespib/docetaxale increased overall survival by 4.3 months over docetaxel alone (10.7 months versus 6.4 months.)

Last September, the hazard ratio was 0.37, or a 63 percent reduction in the risk of death.

Investors have tended to view ganetespib's chances of success with a lot of skepticism because claims the drug would work better in certain targeted subsets of lung cancer patients (elevated LDH or KRAS mutants) have not panned out. The narrowing survival trend from the Galaxy-1 study in data-mined subsets of patients isn't likely to bolster anyone's confidence in Synta's ability to deliver a positive outcome from the pivotal Galaxy-2 study.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,788.61 +69.61 0.39%
S&P 500 2,061.96 +9.21 0.45%
NASDAQ 4,715.2680 +13.4010 0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs